Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant lipocalin-2:siderophore:Fe
- Development stage
- Preclinical
- Lead developer
- Charité Universitätsmedizin Berlin
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Parenteral
01
Overview
Recombinant lipocalin-2:siderophore:Fe (rLcn2) is an iron-loaded recombinant form of lipocalin-2 (Lcn2), also known as neutrophil gelatinase-associated lipocalin (NGAL). It is complexed with a bacterial siderophore (such as enterobactin) and ferric iron (Fe3+). In preclinical models of kidney transplantation and acute kidney injury, perioperative administration of rLcn2 acts as a renoprotective agent. It delivers iron intracellularly to proximal tubular epithelial cells via receptor-mediated endocytosis, which preserves mitochondrial function, prevents apoptosis, and maintains microvascular dilatory function. Additionally, rLcn2 modulates the adaptive immune response by selectively reducing the infiltration and activation of cytotoxic CD8+ T cells and effector memory T cells in the renal allograft, thereby mitigating acute rejection.
- Other names
- holo-rLcn2holo-rLcn-2holo-rLcn 2rLcn2rLcn-2rLcn 2rLcn2:Sid:Fe3+rLcn2:Siderophore:Ferecombinant Lcn2:Siderophore:Ferecombinant lipocalin 2:siderophore:Fe complexrecombinant lipocalin-2:siderophore:Fe3+ complex
02
Targets
LRP2 (Low-density lipoprotein receptor-related protein 2)SLC superfamily (Solute carrier superfamily)
Beyond the preview
Go deeper on recombinant lipocalin-2:siderophore:Fe.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant lipocalin-2:siderophore:Fe.